Results 21 to 30 of about 15,139,370 (299)

Immune‐related Adverse Events in Cancer Patients [PDF]

open access: yesAcademic Emergency Medicine, 2018
AbstractThe U.S. Food and Drug Administration has approved immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR‐T cells) as immunotherapy strategies for cancer. These therapies cause a wide variety of adverse events, which mimic other disease states and may emerge months after completion of treatment.
Daniel J, Pallin   +5 more
openaire   +2 more sources

Immune-related adverse events.

open access: yes, 2022
Immune-related adverse events.
Yuji Miyoshi (3172629)   +5 more
core   +1 more source

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

open access: yesFrontiers in Oncology, 2020
BackgroundImmune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 receptor (PD-1), and programmed death-1 receptor and its ligand (PD-L1) increased the survival of patients affected by metastatic ...
Maria Anna Siciliano   +9 more
doaj   +1 more source

Vasospastic Angina: An Immune-related Adverse Event

open access: yesInternal Medicine, 2022
A 54-year-old Japanese woman was admitted to our ward because of recurrent chest pain at rest for 2 months. She had been treated with nivolumab, an immune checkpoint inhibitor for inoperable advanced hypopharyngeal cancer for 21 months. She had no chest pain after cessation of nivolumab treatment.
Kumamoto, Taku   +6 more
openaire   +3 more sources

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis

open access: yes, 2022
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira   +9 more
core   +1 more source

Immune-related adverse events included in the online application.

open access: yes, 2022
Immune-related adverse events included in the online application.
Ryuji Matsumoto (1992658)   +8 more
core   +1 more source

Details of immune-related adverse events.

open access: yes, 2022
Details of immune-related adverse events.
Yuji Miyoshi (3172629)   +5 more
core   +1 more source

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

open access: yesFrontiers in Immunology, 2023
PurposeTo investigate the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and outcomes of ophthalmic irAEs.MethodsWe retrospectively reviewed the medical ...
Linyang Gan   +3 more
doaj   +1 more source

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

open access: yesOncoImmunology, 2023
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE)
Alisa Lepper   +6 more
doaj   +1 more source

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0

open access: yes, 2022
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo   +22 more
core   +1 more source

Home - About - Disclaimer - Privacy